Natco Pharma, which has seen its stock almost double from March lows, could see more gains. The patent settlement by Dr Reddy’s Laboratories for a mega generic launch of multiple myeloma drug Revlimid in the US recently is positive for Natco, too. The company had a first-to-file status for the drug in four strengths (5, 10, 15, 25 mg) and was also the first to settle with the innovator in 2015, and enjoyed better deal terms, too. However, given the uncertainty around the litigation, the Street had not ascribed any value to the Revlimid opportunity.
While the settlement rem.....
|Key stories on business-standard.com are available to premium subscribers only.|
Already a premium subscriber? LOGIN NOW.
Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.